Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials
We previously reported primary endpoints of two consecutive phase I/II trials, evaluating different schedules of neoadjuvant epirubicin (E), gemcitabine (G) and docetaxel (Doc) for primary breast cancer (PBC). Here, we report mature survival data and prognostic factors. One hundred fifty-one patient...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
7 February 2013
|
| In: |
International journal of cancer
Year: 2013, Volume: 133, Issue: 4, Pages: 1006-1015 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.28094 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.28094 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.28094 
|
| Author Notes: | Frederik Marmé, Julia Aigner, Justo Lorenzo Bermejo, Peter Sinn, Christof Sohn, Dirk Jäger and Andreas Schneeweiss |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1761123718 | ||
| 003 | DE-627 | ||
| 005 | 20230426153104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210623s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.28094 |2 doi | |
| 035 | |a (DE-627)1761123718 | ||
| 035 | |a (DE-599)KXP1761123718 | ||
| 035 | |a (OCoLC)1341416896 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer |b long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials |c Frederik Marmé, Julia Aigner, Justo Lorenzo Bermejo, Peter Sinn, Christof Sohn, Dirk Jäger and Andreas Schneeweiss |
| 264 | 1 | |c 7 February 2013 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.06.2021 | ||
| 520 | |a We previously reported primary endpoints of two consecutive phase I/II trials, evaluating different schedules of neoadjuvant epirubicin (E), gemcitabine (G) and docetaxel (Doc) for primary breast cancer (PBC). Here, we report mature survival data and prognostic factors. One hundred fifty-one patients were recruited into two consecutive phase I/II trials of neoadjuvant chemotherapy for T2-4 N0-2 M0 PBC. Patients received six cycles of G/E/Doc every 3 weeks with G repeated on d8 (GEDoc, n = 84) or five cycles of G/E followed by four cycles of Doc all given every two weeks (GEsDoc, n = 67). Prognostic factors were investigated using univariate and multivariate analyses. No survival differences by treatment were found. Among reported predictive factors for pathologic complete response (pCR), oestrogen receptor (ER) status was the only relevant factor in the multivariate analysis. Unexpectedly, pCR resulted in poorer survival (univariate HR for overall survival [OS] 3.11, p = 0.007). Multivariate analyses identified molecular subtype and tumour size as the most relevant prognostic factors for OS. HER2-receptor status and the CPS-EG score (Mittendorf et al., J Clin Oncol 2011;29:1956-62), based on clinical and pathological stage, ER-status and tumour grade, were particularly relevant in disease-free survival. Our findings cast doubt on the reliability of pCR as single marker for prognosis of this unselected breast cancer cohort, with an abundance of luminal subtypes. These results underline the significance of additional molecular characteristics for breast cancer survival. | ||
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a CPS-EG score | |
| 650 | 4 | |a Ki-67 | |
| 650 | 4 | |a molecular subtypes | |
| 650 | 4 | |a neoadjuvant chemotherapy | |
| 650 | 4 | |a pathologic complete response | |
| 650 | 4 | |a survival | |
| 700 | 1 | |a Aigner, Julia |e VerfasserIn |0 (DE-588)136081274 |0 (DE-627)577147072 |0 (DE-576)284054399 |4 aut | |
| 700 | 1 | |a Lorenzo Bermejo, Justo |d 1972- |e VerfasserIn |0 (DE-588)124754619 |0 (DE-627)706705572 |0 (DE-576)294483632 |4 aut | |
| 700 | 1 | |a Sinn, Peter |d 1957- |e VerfasserIn |0 (DE-588)1022590944 |0 (DE-627)717004783 |0 (DE-576)365646342 |4 aut | |
| 700 | 1 | |a Sohn, Christof |d 1961- |e VerfasserIn |0 (DE-588)131349287 |0 (DE-627)507642902 |0 (DE-576)298422255 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d Bognor Regis : Wiley-Liss, 1966 |g 133(2013), 4, Seite 1006-1015 |h Online-Ressource |w (DE-627)269532781 |w (DE-600)1474822-8 |w (DE-576)079876129 |x 1097-0215 |7 nnas |a Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials |
| 773 | 1 | 8 | |g volume:133 |g year:2013 |g number:4 |g pages:1006-1015 |g extent:10 |a Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials |
| 856 | 4 | 0 | |u https://doi.org/10.1002/ijc.28094 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.28094 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210623 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 7 |y j | ||
| 998 | |g 1032507535 |a Jäger, Dirk |m 1032507535:Jäger, Dirk |d 910000 |e 910000PJ1032507535 |k 0/910000/ |p 6 | ||
| 998 | |g 131349287 |a Sohn, Christof |m 131349287:Sohn, Christof |d 910000 |d 910400 |e 910000PS131349287 |e 910400PS131349287 |k 0/910000/ |k 1/910000/910400/ |p 5 | ||
| 998 | |g 1022590944 |a Sinn, Peter |m 1022590944:Sinn, Peter |d 910000 |d 912000 |d 50000 |e 910000PS1022590944 |e 912000PS1022590944 |e 50000PS1022590944 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 4 | ||
| 998 | |g 124754619 |a Lorenzo Bermejo, Justo |m 124754619:Lorenzo Bermejo, Justo |d 910000 |d 999701 |d 50000 |e 910000PL124754619 |e 999701PL124754619 |e 50000PL124754619 |k 0/910000/ |k 1/910000/999701/ |k 0/50000/ |p 3 | ||
| 998 | |g 136081274 |a Aigner, Julia |m 136081274:Aigner, Julia |d 50000 |e 50000PA136081274 |k 0/50000/ |p 2 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1761123718 |e 3940957615 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"7 February 2013"}],"title":[{"title_sort":"Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer","subtitle":"long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials","title":"Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer"}],"person":[{"display":"Marmé, Frederik","family":"Marmé","given":"Frederik","role":"aut"},{"family":"Aigner","given":"Julia","display":"Aigner, Julia","role":"aut"},{"role":"aut","display":"Lorenzo Bermejo, Justo","given":"Justo","family":"Lorenzo Bermejo"},{"role":"aut","family":"Sinn","given":"Peter","display":"Sinn, Peter"},{"role":"aut","display":"Sohn, Christof","given":"Christof","family":"Sohn"},{"role":"aut","display":"Jäger, Dirk","family":"Jäger","given":"Dirk"},{"display":"Schneeweiss, Andreas","family":"Schneeweiss","given":"Andreas","role":"aut"}],"note":["Gesehen am 23.06.2021"],"relHost":[{"note":["Gesehen am 28.02.08","Darin: Predictive oncology"],"origin":[{"dateIssuedKey":"1966","publisherPlace":"Bognor Regis","dateIssuedDisp":"1966-","publisher":"Wiley-Liss"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1966 -"],"title":[{"title":"International journal of cancer","title_sort":"International journal of cancer","subtitle":"publication of the International Union against Cancer (UICC) = Journal international du cancer"}],"language":["eng"],"part":{"text":"133(2013), 4, Seite 1006-1015","year":"2013","issue":"4","extent":"10","volume":"133","pages":"1006-1015"},"corporate":[{"role":"isb","display":"International Union against Cancer"}],"titleTranslated":[{"translated":"Journal international du cancer"}],"disp":"Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trialsInternational journal of cancer","physDesc":[{"extent":"Online-Ressource"}],"titleAlt":[{"title":"Predictive oncology"}],"recId":"269532781","id":{"eki":["269532781"],"doi":["10.1002/(ISSN)1097-0215"],"zdb":["1474822-8"],"issn":["1097-0215"]}}],"name":{"displayForm":["Frederik Marmé, Julia Aigner, Justo Lorenzo Bermejo, Peter Sinn, Christof Sohn, Dirk Jäger and Andreas Schneeweiss"]},"id":{"eki":["1761123718"],"doi":["10.1002/ijc.28094"]},"recId":"1761123718","language":["eng"],"physDesc":[{"extent":"10 S."}]} | ||
| SRT | |a MARMEFREDENEOADJUVAN7201 | ||